| Recruiting | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic NCT06998940 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combinati NCT07157033 | Xerient Pharma | Phase 1 / Phase 2 |
| Recruiting | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic NCT06861088 | Quercis Pharma AG | Phase 3 |
| Recruiting | Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced a NCT07076212 | Medical University of South Carolina | Phase 2 |
| Not Yet Recruiting | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers NCT07097064 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Recruiting | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancrea NCT06861452 | EIR Biotherapies s.r.l. | Phase 1 / Phase 2 |
| Recruiting | Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer NCT06850623 | EXACT Therapeutics AS | Phase 2 |
| Recruiting | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017 | PanTher Therapeutics | Phase 1 |
| Recruiting | A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemot NCT06453486 | University Health Network, Toronto | Phase 2 |
| Recruiting | Surgery for Locally Unresectable Pancreatic Cancer NCT07241663 | Azienda Ospedaliera di Padova | — |
| Recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally A NCT06381154 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy NCT06399172 | OncoSil Medical Limited | — |
| Not Yet Recruiting | Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy NCT06272162 | UMC Utrecht | N/A |
| Active Not Recruiting | PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvan NCT06132087 | University of Southern California | N/A |
| Recruiting | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC NCT06714604 | Sahlgrenska University Hospital | Phase 3 |
| Recruiting | Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer NCT05679674 | Baptist Health South Florida | N/A |
| Recruiting | Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05825066 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic A NCT05607953 | TriSalus Life Sciences, Inc. | Phase 1 |
| Active Not Recruiting | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT05034627 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer NCT05356039 | Umeå University | — |
| Unknown | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer NCT04617821 | Fudan University | Phase 3 |
| Recruiting | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer NCT05524090 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Pati NCT04570943 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Active Not Recruiting | FAZA PET/MRI Pancreas NCT04395469 | University Health Network, Toronto | N/A |
| Unknown | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer NCT04718701 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With NCT04172532 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer NCT04665947 | University of California, Davis | EARLY_Phase 1 |
| Active Not Recruiting | Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancr NCT04669197 | HonorHealth Research Institute | Phase 2 |
| Unknown | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab NCT04652206 | Scandion Oncology A/S | Phase 1 / Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC NCT03673137 | Fuda Cancer Hospital, Guangzhou | Phase 2 / Phase 3 |
| Withdrawn | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer NCT03536182 | University of Texas Southwestern Medical Center | Phase 3 |
| Active Not Recruiting | Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) NCT04423731 | Oslo University Hospital | — |
| Completed | Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma NCT03077685 | NanOlogy, LLC | Phase 2 |
| Active Not Recruiting | BATs Treatment for Pancreatic Cancer, Phase Ib/II NCT03269526 | University of Virginia | Phase 1 / Phase 2 |
| Completed | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With NCT02394535 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With NCT01585805 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Immunochemoradiotherapy in Patients With Pancreatic Cancer NCT01342224 | Providence Health & Services | Phase 1 |
| Active Not Recruiting | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery NCT00669734 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection NCT01278368 | Università Vita-Salute San Raffaele | N/A |
| Temporarily Not Available | Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Pacl NCT07319910 | NovoCure GmbH | — |